Relationships with DOS and PFI
. | DOS . | PFI . | . | . | ||
|---|---|---|---|---|---|---|
. | CD38 . | CD38 . | Ki67 . | SYK . | ||
| n, +/−* | 22/22 | 22/22 | 21/21 | 20/23 | ||
| Events, no., +/− | 2/9 | 6/13 | 7/12 | 7/12 | ||
| HR (% CI) | 5.33 (1.15-24.81) | 3.32 (1.17-9.39) | 3.22 (1.19-8.68) | 0.34 (0.12-0.99) | ||
| P | .033 | .024 | .021 | .048 | ||
. | DOS . | PFI . | . | . | ||
|---|---|---|---|---|---|---|
. | CD38 . | CD38 . | Ki67 . | SYK . | ||
| n, +/−* | 22/22 | 22/22 | 21/21 | 20/23 | ||
| Events, no., +/− | 2/9 | 6/13 | 7/12 | 7/12 | ||
| HR (% CI) | 5.33 (1.15-24.81) | 3.32 (1.17-9.39) | 3.22 (1.19-8.68) | 0.34 (0.12-0.99) | ||
| P | .033 | .024 | .021 | .048 | ||
The number of patients (n) and events observed in each group, estimated HR computed via the univariate Cox model, and the associated P values are indicated.
For CD38, Ki67, and SYK, + indicates high expression and − indicates low expression.